Differential promoter usage for insulin-like growth factor-II gene in Chinese hepatocellular carcinoma with hepatitis B virus infection

Tang, Shao; Yan, Dong; Huang, Wei; Zhou, Min; Zhou, Hong; Lu, Xinli; Ye, Gang

doi:10.1016/j.cdp.2005.12.004

Cited by 15 publications

(24 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all 15 samples of human HCC tested in a study, the overexpression of maternally imprinted fetal IGF-2 was demonstrated [51]. In a study from Hong Kong, 30 HCC samples from patients examined using northern blot analysis showed more than 93% of the adult promoter IGF-2 transcripts were repressed, while 93% of the adult type IGF-2 transcripts were detected in nontumourous tissues [68,69]. …”

Section: Physiologic Functions Of Igf Ligands and Receptorsmentioning

confidence: 99%

Targeting insulin-like growth factor axis in hepatocellular carcinoma

Wu¹,

Zhu

2011

J Hematol Oncol

View full text Add to dashboard Cite

The insulin-like growth factor (IGF) axis contains ligands, receptors, substrates, and ligand binding proteins. The essential role of IGF axis in hepatocellular carcinoma (HCC) has been illustrated in HCC cell lines and in animal xenograft models. Preclinical evidence provides ample indication that all four components of IGF axis are crucial in the carcinogenic and metastatic potential of HCC. Several strategies targeting this system including monoclonal antibodies against the IGF 1 receptor (IGF-1R) and small molecule inhibitors of the tyrosine kinase function of IGF-1R are under active investigation. This review describes the most up-to-date understanding of this complex axis in HCC, and provides relevant information on clinical trials targeting the IGF axis in HCC with a focus on anti-IGF-1R approach. IGF axis is increasingly recognized as one of the most relevant pathways in HCC and agents targeting this axis can potentially play an important role in the treatment of HCC.

show abstract

Section: Physiologic Functions Of Igf Ligands and Receptorsmentioning

confidence: 99%

Targeting insulin-like growth factor axis in hepatocellular carcinoma

Wu¹,

Zhu

2011

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…Loss of imprinting (LOI), defined as aberrant expression of the normally silent maternally inherited allele, is an epigenetic mechanism that leads to the overexpression of IGF-II. LOI of IGF-II has been reported to be associated with increased susceptibility to CRC and more advanced disease in several cancers (23)(24)(25)(26). However, whether LOI of IGF-II is associated with survival in patients with CRC has not been reported.…”

mentioning

confidence: 99%

Plasma Insulin-Like Growth Factor-Binding Protein-2 Levels as Diagnostic and Prognostic Biomarker of Colorectal Cancer

Liou

Shun

Liang

et al. 2010

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

“…These promoters, however, are found to be reactivated in cancer. Studies have shown elevated P3 expression in several malignancies (17)(18)(19)(20), and P3 demethylation plays a critical role in reactivation of P3 expression (21,22). Our study showed that levels of IGF-II mRNA and peptide were substantially different among patients with distinct methylation patterns in P2 and P3.…”

Section: Discussionmentioning

confidence: 49%

IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics

Qian

Katsaros²,

Lu³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. High expression of insulin-like growth factor-II (IGF-II) in epithelial ovarian cancer is associated with aggressive disease and poor prognosis. IGF-II transcription is initiated from multiple promoters. Promoter-specific expression is regulated by DNA methylation, which is often dysregulated in cancer. Here, the effects of promoter-specific methylation on IGF-II expression are investigated in ovarian cancer. Fresh tumor samples were collected from 211 patients for analyses of IGF-II promoter methylation using methylationspecific PCR, and of promoter-specific expression of IGF-II mRNA with qRT-PCR, as well as tissue levels of IGF-II peptide with an ELISA. Cox regression analysis was performed to assess IGF-II methylation and expression in association with progression-free and overall survival. DNA methylation was high in IGF-II promoters 2 (P2, 64.2%) and 3 (P3, 52.1%) and low in promoter 4 (P4, 9.8%). High methylation was associated with low mRNA expression in a promoter-specific manner. P3 methylation and expression appeared to be critical in ovarian cancer compared to other promoters. While methylation in an individual promoter was not associated with the disease, a methylation pattern involving P2 and P3 was significantly different among patients with distinct tumor grade, debulking results, residual tumor size and treatment response. The methylation pattern was also associated with disease progression. The study suggests that DNA methylation regulates IGF-II promoter-specific expression in ovarian cancer and the regulation may play a role in disease progression. Assessing methylation patterns in IGF-II promoters may have clinical implications.

show abstract

Differential promoter usage for insulin-like growth factor-II gene in Chinese hepatocellular carcinoma with hepatitis B virus infection

Cited by 15 publications

References 37 publications

Targeting insulin-like growth factor axis in hepatocellular carcinoma

Targeting insulin-like growth factor axis in hepatocellular carcinoma

Plasma Insulin-Like Growth Factor-Binding Protein-2 Levels as Diagnostic and Prognostic Biomarker of Colorectal Cancer

IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics

Contact Info

Product

Resources

About